How to access Spinraza from India — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient — infant, child, or adult — with spinal muscular atrophy (SMA) confirmed by biallelic SMN1 mutations may receive a prescription for Spinraza (nusinersen) from their treating paediatric or adult neurologist. Spinraza is FDA-approved, developed by Biogen, and is an intrathecally administered antisense oligonucleotide that modulates SMN2 splicing to increase functional SMN protein production. Because Spinraza requires chronic intrathecal administration and specialised dosing logistics, access involves both the import pathway and a sustained relationship with a paediatric or adult neurology service capable of lumbar-puncture administration.
This guide explains the legal pathway, what your physician needs to provide, typical timelines, and where Reserve Meds fits in.
The clinical situation
Spinraza is administered by intrathecal injection on a loading schedule of four doses (days 0, 14, 28, and 63) followed by maintenance dosing every four months thereafter, indefinitely. Each dose requires a trained operator performing lumbar puncture with appropriate sedation and imaging support where needed, particularly in older children with spinal-fusion complications or paediatric anaesthesia considerations. Eligibility anchors to SMN1 biallelic mutation confirmation and clinical or pre-symptomatic SMA. Baseline assessment includes coagulation parameters, renal function, and platelet count with ongoing monitoring per label. Your neurology team will plan the lumbar-puncture cadence and coordinate sedation or imaging support as needed.
Is Spinraza legally importable into India?
Yes — via the Central Drugs Standard Control Organisation (CDSCO) Personal Use / Named-Patient import framework. The mechanism permits a treating physician to import a medicine not yet locally registered when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent alternative is routinely available, (c) the physician accepts clinical responsibility, and (d) chain of custody through a licensed importer is documented.
For Spinraza specifically, the application is well-suited to multi-dose scheduling: CDSCO personal-use approvals support the scheduled-dose cadence with renewed applications aligned to the maintenance calendar.
How the pathway works, step by step
- Consultation with your paediatric or adult neurologist. SMN1 confirmation, clinical SMA type, prior therapy documentation, lumbar-puncture feasibility assessment, clinical rationale letter.
- Administering-centre identification. A neurology centre with intrathecal administration capability — including sedation and imaging support as needed — is nominated.
- CDSCO personal-use import application. Your physician or the importing licensed pharmacy files the dossier including rationale, patient reference, loading-plus-maintenance dosing plan, and administering-centre attestation.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Spinraza from the manufacturer's authorised distribution chain under DSCSA.
- Cold-chain shipment. Spinraza ships with validated temperature control to the administering hospital pharmacy, timed to the scheduled dose.
- Intrathecal administration and ongoing cadence. The neurology team delivers each dose per schedule.
What documentation your physician needs
- Clinical rationale letter confirming SMA diagnosis, SMN1 biallelic status, clinical SMA type, and Spinraza as the indicated therapy
- Verification of NMC / MCI registration
- SMN1 molecular-testing report
- Baseline coagulation, platelet count, and renal function
- Identification of the administering neurology centre with intrathecal capability
- Loading (doses 1–4) plus every-four-month maintenance dosing plan
Reserve Meds provides a physician documentation kit bundling the CDSCO templates reviewers expect to see for SMA named-patient files, designed around the recurring maintenance cadence.
Costs and timing
Spinraza's US cash-pay reference cost in an indicative 2026 range is roughly USD 125,000 per dose (pre-rebate list-anchored); the first year (six doses: four loading plus two maintenance) therefore anchors near USD 700,000–750,000, and subsequent annual maintenance (three doses/year) near USD 375,000–380,000. International logistics, CDSCO documentation handling, importer-of-record fees, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. These figures are indicative, not guaranteed.
Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 14–28 days from the moment a complete CDSCO application is submitted. Subsequent maintenance doses run on the scheduled calendar.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: Spinraza maintenance is a chronic commitment and families in India often travel to a specific neurology centre for every dose. Our coordination accounts for that travel pattern and focuses on predictable scheduling around the every-four-month cadence.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and CDSCO review, keyed to the SMA rationale and multi-dose schedule.
- Logistics. Cold-chain shipment to the administering centre, timed to each scheduled dose.
- Concierge case lead. A named point of contact maintaining case continuity across the loading phase and into long-term maintenance.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy or administering centre. All clinical decisions remain with your treating neurologist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
How does Spinraza compare with Evrysdi? Evrysdi is an oral daily liquid therapy addressing the same molecular target through SMN2 splice modulation. Your neurologist will select based on age, spinal anatomy (intrathecal feasibility), caregiver preference, and clinical picture. Families sometimes switch between the two.
My child has had Zolgensma — are they still candidates for Spinraza? Sequential therapy is not a contraindication; some families choose add-on nusinersen after gene therapy. Your neurologist decides.
What about the lumbar-puncture burden? In older children with spinal fusion or difficult anatomy, imaging-guided administration and specialised sedation protocols are used. Your administering centre will plan.
Will insurance or philanthropy cover this? Cash-pay is the default for named-patient imports. Some Indian private insurers and SMA philanthropic programmes consider case-by-case support; we supply documentation but do not manage funding directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Spinraza coordination.
Add me to the Spinraza waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.